Rapalogix Health, a Carlsbad, California-based biotechnology company focused on cellular longevity and skin health, announced it closed a $20 million Series A financing. The round was co-led by GordonMD Global Investments LP and Woodline Partners.
GordonMD is a Beverly Hills-based physician-led biopharma investment firm focused on differentiated biology, precision medicine, novel therapeutic platforms, and clinical-stage companies. The firm identified Rapalogix as a portfolio priority based on the scientific rigor of its TORC1-targeting platform.
The proceeds will be used to support the national commercial expansion of Re-Q Health and advance IND-enabling development of RLX-202, the company’s lead prescription therapeutic candidate for aesthetic dermatology.
Rapalogix’s lead molecule, RLX-201, is a patented pro-longevity compound designed to restore youthful cellular function through the modulation of TORC1 activity in the skin. Re-Q Pro-Longevity Face Serum, which is powered by RLX-201, launched nationally on May 14, 2026, and is currently available through dermatology and aesthetic practices across the United States.
The financing also follows strong industry recognition for Rapalogix, including four 2026 awards: First Place at the IMCAS Innovation Tank in Paris, the Judges’ Choice Award at Octane’s Aesthetics Tech Forum, Start-Up of the Year at the INNOCOS Beauty, Tech & Longevity Summit, and the Catalyst Award at AMWC in Monaco.
KEY QUOTES:
“As a physician-investor focused on differentiated biology, I look for companies where the mechanism of action is the competitive advantage. Rapalogix has that in RLX-201. The science underlying their platform has the potential to redefine how we treat skin aging — both in the aesthetics office and, eventually, in the clinic.”
Craig Gordon, MD, Founder, CEO and CIO of GordonMD Global Investments
“This financing marks a significant milestone for Rapalogix and reflects the strength of the science underlying our platform. This capital enables us to bring our cellular longevity vision to more patients and physicians across the country while advancing our next generation of therapeutics.”
Rahul Mehta, PhD, Co-Founder and CEO of Rapalogix Health
